$TCRT

Biotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).

Alaunos Therapeutics (NASDAQ: TCRT) has filed an amended annual report (10-K/A) to provide detailed information on its board structure, executive and director compensation, and significant shareholder ownership, which was initially omitted from its original 10-K filing. The amendment reaffirms a four-member board led by CEO Holger Weis and outlines various agreements, equity incentive plans, and audit fees, without altering previously reported financial statements. Key figures include a market value of non-affiliate holdings at $9.6 million and Robert W. Postma as the largest beneficial owner with 18.28% of shares.

Alaunos Therapeutics (NASDAQ:TCRT) has received a notice from Nasdaq for non-compliance with its listing rule requiring a minimum of $2.5 million in stockholders’ equity, as the company reported $2.153 million. The company must submit a compliance plan within 45 days and is exploring options to regain compliance, though there's no guarantee of acceptance or successful resolution. Non-compliance could lead to delisting, but Alaunos would have the right to appeal before a Nasdaq hearings panel.

Alaunos Therapeutics reported minimal revenue and a net loss for the year, primarily due to operating expenses. The company has pivoted its programs from oncology to an obesity/metabolic program, which has shown promising preclinical results. Future advancement of this program is contingent on securing additional capital and strategic partnerships.

This Simply Wall St analysis provides an overview of Alaunos Therapeutics (Nasdaq:TCRT), a clinical-stage oncology-focused cell therapy company with a market cap of US$6.7m. The report details its financials, including a current share price of US$2.98, recent news, and performance metrics. While the company has shown earnings growth, it faces risks such as a limited cash runway and past shareholder dilution.

Shares of Richardson Electronics, Ltd. ( NASDAQ:RELL ) rose sharply in pre-market trading after the company reported better-than-expected first-quarter financial results. Richardson Electronics reported quarterly earnings of 13 cents per share which beat the analyst consensus estimate of 1 ...

PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies ...

NEWPORT BEACH, Calif., May 14, 2025 ( GLOBE NEWSWIRE ) -- PMGC Capital LLC ( "PMGC Capital," "we," "our," or "us" ) , a wholly owned subsidiary of PMGC Holdings Inc. ELAB, today announced its planned filing of a Schedule 13D with the U.S.